Scisparc Ltd., formerly known as Therapix Biosciences Ltd., is a pharmaceutical company headquartered in Tel Aviv, Israel. The company focuses on the development of proprietary cannabinoid-based therapies to address various medical conditions, including neurological and psychiatric disorders. Scisparc is at the forefront of research and innovation in the field of cannabinoid-based medicine, with a commitment to improving patient outcomes and addressing unmet medical needs.
One of Scisparc's key therapeutic candidates is THX-110, an investigational drug designed for the treatment of Tourette Syndrome (TS). Tourette Syndrome is a neurological disorder characterized by repetitive, involuntary movements and vocalizations known as tics. THX-110 aims to provide relief to individuals with TS by targeting specific receptors in the brain's endocannabinoid system, potentially reducing the severity and frequency of tics.
Scisparc has conducted clinical trials to assess the safety and efficacy of THX-110 in individuals with TS. The company's research and development efforts have shown promising results, suggesting that THX-110 could become a valuable treatment option for TS patients.
Beyond Tourette Syndrome, Scisparc explores the therapeutic potential of cannabinoids in other neurological and psychiatric conditions, including mild cognitive impairment (MCI) and chronic pain. The company's commitment to research and development extends to exploring the broader applications of cannabinoids in the healthcare landscape.
Scisparc's work aligns with the growing interest in medical cannabis and cannabinoid-based treatments as potential alternatives or supplements to traditional pharmaceuticals. The company's dedication to advancing the understanding of cannabinoids' medical benefits reflects its mission to improve the lives of patients by developing innovative, evidence-based therapies.